Rodman & Renshaw Downgardes Bioenvision (BIVN) to Market Perform
More News related to BIVN
- Wachovia Starts Bioenvision (BIVN) at Market Perform
- Bioenvision (BIVN) Reports a Q4 Loss
- Bioenvision's (BIVN) Former General Counsel Files Action in NY Supreme Court Against the Company
- Genzyme (GENZ) Announces Completion of Tender Offer for Bioenvision
- Rodman & Renshaw Downgardes Bioenvision (BIVN) to Market Perform
More News related to GENZ
- Genzyme (GENZ) CEO Dumps 200K Shares As Company Deals With Manufacturing Issues
- InvestorSoup.com Issues Technical Trading Outlook for ARCA biopharma Inc.
- Morgan Joseph Reiterates a 'Buy' on Isis Pharmaceuticals (ISIS); Could Be Acquired by Potential Partners
- Piper Jaffray Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); Price Target Cut
- Genzyme Corp. (GENZ) Announces Reports on Phase 2/3 for Advanced Phosphate Binder
More News related to Downgrades
- Ford (F) and Geely Reportedly Clear Hurdle On Possible Volvo Deal
- Starent Networks (STAR) To Settle Shareholder Class Action Suit In Connection With Proposed Merger with Cisco (CSCO)
- Hurray! Holding (HRAY) To Acquire Ku6 in All Stock Transaction
Rodman & Renshaw downgardes Bioenvision (NASDAQ: BIVN) from Market Outperform to Market Perform. The analyst does not expect the stock price of Bioenvision (NASDAQ: BIVN) to increase due to the fact that the shareholders of Bioenvision are expected to accept the $345 million bid from Genzyme (NASDAQ: GENZ). The firm does not expect a higher bid.
Related Categories
DowngradesStocks Mentioned
-0.03
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
